



10 July 2019

To  
**Listing Compliance Department**  
National Stock Exchange of India Ltd.  
Exchange Plaza,  
Plot no.C/1, G Block,  
Bandra- Kurla Complex, Bandra (E)  
Mumbai- 400051

**Subject: Clarification on the email received from the Exchange on July 4, 2019 regarding clarification relating to the announcement submitted the exchange on May 28, 2019 regarding the outcome of the Board Meeting held on May 28, 2019**

Dear Sir/ Madam,

With respect to the captioned query that we have received from your esteemed offices relating to the announcement made on the commencement of pathology business on May 28, 2019, we wish to clarify that Aster DM Healthcare Limited ('the Company') has decided to provide the pathology and allied services through a separate entity to other outside patients, in addition to the pathology services offered in the already existing hospitals and clinics which was only being offered to our patients. This shall not be understood as a new line of business entered by the Company.

Further, we have also made a disclosure on July 5, 2019 relating to the incorporation of a Limited Liability Partnership in India, Aster Clinical Lab LLP, for carrying on the business of pathology and allied services. The details required as per Circular Number CIR/CFD/CMD/4/2015 dated September 09, 2015 pertaining to the estimated amount of investment and other details have also been enclosed along with the disclosure made on July 5, 2019.

We request you to take the same on record and oblige

for **Aster DM HealthCare Limited**

Puja Aggarwal  
Company Secretary & Compliance Officer

**Aster DM Healthcare Limited**  
CIN- L85110KL2008PLC021703  
IX/475L, Aster Medcity, Kuttisahib Road  
Near Kothad Bridge, South Chittoor PO  
Cheranallor, Kochi- 682027, Kerala, India  
Tel: +91 484 6699999, Fax: +91 484 6699862  
Email: cs@asterdmhealthcare.com